Serum messenger RNA as a biomarker and its clinical usefulness in malignancies

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 511-527

  Miura, Norimasa ^a   Hasegawa, Junichi ^a   Shiota, Goshi ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Cancer diagnosis; hTERT; Malignancy; Real time RT PCR; Tumor marker

Indexed keywords

EID: 78549289575     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s379     Document Type: Review

References (46)

1. Leon, S.A., Shapiro, B., Sklaroff, D.M. and Yaros, M.J. 1977. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37:646-50.
2. Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Beljanski, M. 1989. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology, 46:318-22.
3. Anker, P., Mulcahy, H., Chen, X.Q. and Stroun, M. 1999. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev., 18:65-73. Review.
4. Lo, Y.M., Chan, L.Y., Lo, K.W., Leung, S.F., Zhang, J., Chan, A.T., Lee, J.C., Hjelm, N.M., Johnson, P.J. and Huang, D.P. 1999. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res., 15;59:1188-91.
5. Miura, N., Maeda, Y., Kanbe, T., Yazama, H., Takeda, Y., Sato, R., Tsukamoto, T., Sato, E., Marumoto, A., Harada, T., Sano, A., Kishimoto, Y., Hirooka, Y., Murawaki, Y., Hasegawa, J. and Shiota, G. 2005. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin. Cancer Res., 11:3205-9.
6. Silva, J., Silva, J.M., Garcia, V., Garcia, J.M., Dominguez, G. and Bonilla, F. 2002. RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes Chromosomes Cancer, 35:375-6.
7. Kopreski, M.S., Benko, F.A., Kwak, L.W. and Gocke, C.D. 1999. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res., 5:1961-5.
8. Chen, X.Q., Bonnefoi, H., Pelte, M.F., Lyautey, J., Lederrey, C., Movarekhi, S., Schaeffer, P., Mulcahy, H.E., Meyer, P., Stroun, M. and Anker, P. 2000. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res., 6:3823-6.
9. Dasi, F., Lledo, S., Garcia-Granero, E., Ripoll, R., Marugan, M., Tormo, M., Garcia-Conde, J. and Alino, S.F. 2001. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab. Invest., 81:767-9.
10. Silva, J.M., Dominguez, G., Silva, J., Garcia, J.M., Sanchez, A., Rodriguez, O., Provencio, M., Espana, P. and Bonilla, F. 2001. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin. Cancer Res., 7:2821-5.
11. Kopreski, M.S., Benko, F.A. and Gocke, C.D. 2001. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann. N. Y. Acad. Sci., 945:172-8.
12. Gal, S., Fidler, C., Lo, Y.M., Chin, K., Moore, J., Harris, A.L. and Wainscoat, J.S. 2001. Detection of gammaglobulin mRNA in the plasma of breast cancer patients. Ann. N.Y. Acad. Sci., 945:192-4.
13. Fleischhacker, M., Beinert, T., Ermitsch, M., Seferi, D., Possinger, K., Engelmann, C. and Jandrig, B. 2001. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann. N. Y. Acad. Sci., 945:179-88.
14. Hasselmann, D.O., Rappl, G., Rossler, M., Ugurel, S., Tilgen, W. and Reinhold, U. 2001. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol. Rep., 8:115-8.
15. Silva, J.M., Dominguez, G., Garcia, J.M., Gonzalez, R., Villanueva, M.J., Navarro, F., Provencio, M., San Martin, S., Espana, P. and Bonilla, F. 1999. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res., 59:3251-6.
16. Miura, N., Shiota, G., Nakagawa, T., Sano, A., Marumoto, A., Kishimoto, Y. et al. 2003. Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology, 64:430-4.
17. El-Serag, H.B. and Mason, A.C. 1999. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med., 340:745-50.
18. Shirabe, K., Takenaka, K., Taketomi, A., Kawahara, N., Yamamoto, K., Shimada, M. et al. 1996. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer, 15(77):1050-5.
19. Collier, J. and Sherman, M. 1998. Screening of hepatocellular carcinoma. Hepatology, 37:273-8.
20. Dohmen, K., Shirahama, M., Onohama, S., Miyamaoto, Y., Torii, Y., Irie, K. et al. 2000. Differences in survival based on the type of follow-up for the detection of hepatocellular carcinoma: an analysis of 547 patients. Hepatol. Res., 18:110-21.
21. Okuda, H., Nakanishi, T., Takatsu, K., Saito, A., Hayashi, N., Yamamoto, M., Takasaki, K. and Nakano, M. 2002. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for a-fetoprotein-L3 and seronegative for 12 des-g-carboxyprothrombin in comparison with those seropositive for des-g-carboxy prothrombin alone. J. Gastroenterol. Hepatol, 17:772-8.
22. Srivastava, S. and Gopal-Srivastava, R. 2002. Biomarkers in cancer screening: a public health perspective. J. Nutr., 132(8 Suppl):2471S-5S. Review.
23. Srinivas, P.R., Kramer, B.S. and Srivastava, S. 2001. Trends in biomarker research for cancer detection. Lancet Oncol., 2:698-704. Review.
24. Ng, E.K., Tsui, N.B., Lam, N.Y., Chiu, R.W., Yu, S.C., Wong, S.C. et al. 2002. Presence of filterable and non filterable mRNA in the plasma of cancer patients and healthy individuals. Clin. Chem., 48:1212-7.
25. Tsui, N.B., Ng, E.K. and Lo, Y.M. 2002. Stability of Endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem., 48:1647-53.
26. Tatsuma, T., Goto, S., Kitano, S., Lin, Y.C., Lee, C.M. and Chen, C.L. 2000. Telomerase activity in peripheral blood for diagnosis of hepatoma. J. Gastroenterol. Hepatol., 15:1064-70.
27. Miura, N., Horikawa, I., Nishimoto, A., Ohmura, H., Ito, H., Hirohashi, S. et al. 1997. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet., 93:56-62.
28. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. and Thun, M.J. 2005. Cancer statistics. C.A Cancer J. Clin., 55:10-30.
29. Niloff, J.M., Knapp, R.C., Schaetzl, E., Reynolds, C.and Bast, R.C. Jr., 1984. CA125 antigen levels in obstetric and gynecologic patients. Obstet. Gynecol., 64:703-7.
30. Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Beljanski, M. 1989. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology, 46:318-22.
31. Anker, P., Mulcahy, H., Chen, X.Q. and Stroun, M. 1999. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev., 18:65-73.
32. Bravaccini, S., Sanchini, M.A., Amadori, A., Medri, L., Saragoni, L., Calistri, D., Monti, F., Volpi, A. and Amadori, D. 2005. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J. Clin. Pathol., 58:911-4.
33. Kolquist, K.A., Ellisen, L.W., Counter, C.M., Meyerson, M., Tan, L.K., Weinberg, R.A. et al. 1998. Expression of TERT in early premalignant lesion and a subset of cells in normal tissues. Nat. Genet., 19:182-6.
34. Sozzi, G., Conte, D., Leon, M., Ciricione, R., Roz, L., Ratcliffe, C. et al. 2003. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol., 21:3902-8.
35. Kawakami, T., Okamoto, K., Ogawa, O. and Okada, Y. 2004. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet, 363:40-2.
36. Park, T.W., Riethdorf, S., Riethdorf, L., Loning, T. and Janicke, F. 1999. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int. J. Cancer, 84:426-31.
37. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. and Thun, M.J. 2005. Cancer statistics. CA. Cancer J. Clin., 55:10-30.
38. Niloff, J.M., Knapp, R.C., Schaetzl, E., Reynolds, C.and Bast, R.C. Jr., 1984. CA125 antigen levels in obstetric and gynecologic patients. Obstet. Gynecol., 64:703-7.
39. Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Beljanski, M. 1989. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology, 46:318-22.
40. Anker, P., Mulcahy, H., Chen, X.Q. and Stroun, M. 1999. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev., 18:65-73.
41. Bravaccini, S., Sanchini, M.A., Amadori, A., Medri, L., Saragoni, L., Calistri, D., Monti, F., Volpi, A. and Amadori, D. 2005. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J. Clin. Pathol., 58:911-4.
42. Peng, S.Y., Chen, W.J., Lai, P.L., Jeng, Y.M., Sheu, J.C. and Hsu, H.C. 2004. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer, 112:44-50.
43. Takahashi, S., Kitamoto, M., Takaishi, H., Aikata, H., Kawakami, Y., Nakanishi, T. et al. 2000. Expression of telomerase component genes in hepatocellular carcinoma. Eur. J. Cancer, 36:496-502.
44. Waguri, N., Suda, T., Nomoto, M., Kawai, H., Mita, Y., Kuroiwa, T. et al. 2003. Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Cancer Res., 9:3004-11.
45. Fujita, Y., Fujikane, T., Fujiuchi, S., Nishigaki, Y., Yamazaki, Y., Nagase, A. et al. 2003. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with non small cell lung carcinoma. Cancer, 98:1008-13.
46. Miura, N., Kabashima, H., Shimizu, M., Sato, R., Tsukamoto, T., Harada, T. et al. 2008. Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis. Hepatol. Int., 2:213-21.